Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

US6946130B2 · kind B2 · utility

Assignees

• SmithKline Beecham Limited · US
• SmithKline Beeacham P.L.C. · GB

Inventors

• Robert S. Ames · Havertown, US
• Edward Appelbaum · Blue Bell, US
• Irwin M. Chaiken · Gladwyne, US
• Richard M. Cook · Chester Springs, US
• Mitchell Stuart Gross · Wayne, US
• Stephen Dudley Holmes · Epsom, GB
• Lynette Jane McMillan · Ardmore, US
• Timothy Wayne Theisen · Phoenixville, US

Key dates

• Filing date: Nov 4, 2003
• Grant date: Sep 20, 2005
• Expiry date: Nov 4, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.